| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.05. | CytomX Therapeutics, Inc. (CTMX) Q1 2024 Earnings Call Transcript | 31 | Insider Monkey | ||
| 09.05. | Analysts' Varied Perspectives On CytomX's CX-904 Cancer Study: Safety Profile But Caution in Pancreatic Cancer | 24 | Benzinga.com | ||
| 09.05. | CytomX stock down 30% despite encouraging cancer study results | 45 | iNVEZZ.com | ||
| 08.05. | CytomX Therapeutics, Inc. - 8-K, Current Report | 23 | SEC Filings | ||
| 08.05. | CytomX Therapeutics Inc.: CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY T-Cell Engager) | 108 | GlobeNewswire (Europe) | - CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall - - Encouraging initial signs... ► Artikel lesen | |
| 08.05. | CytomX Therapeutics Inc.: CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update | 78 | GlobeNewswire (Europe) | - Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors - - First dose cohort cleared in Phase 1 clinical study of CX-2051... ► Artikel lesen | |
| 08.05. | CytomX Therapeutics, Inc. - 10-Q, Quarterly Report | 8 | SEC Filings | ||
| 07.05. | CytomX Therapeutics Inc.: CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA (pembrolizumab) | 146 | GlobeNewswire (Europe) | - CX-801 is a dually masked, conditionally activated IFNa2b cytokine designed using the CytomX Probody® Therapeutic Platform - - Phase 1 first-in-human study expected to start in... ► Artikel lesen | |
| 06.05. | CytomX raised to buy at Jefferies in anticipation of phase 1 solid tumors asset data | 22 | Seeking Alpha | ||
| 02.05. | CytomX Therapeutics, Allarity Therapeutics, Pulmonx among healthcare movers | 22 | Seeking Alpha | ||
| 02.05. | CytomX-Aktie +259%: Top-Empfehlung dreht völlig durch! | 633 | sharedeals.de | Mit der Aktie des Biotech-Unternehmens CytomX Therapeutics (WKN: A14158) knallt einer unserer Top-Tipps am Mittwoch in der Spitze um +259% von 1,63 US$ bis auf 5,85 US$ in die Höhe - bei absoluten Rekordumsätzen... ► Artikel lesen | |
| 01.05. | What's Going On With CytomX Stock? | 48 | Benzinga.com | ||
| 01.05. | CytomX surges on upcoming data for Amgen-partnered cancer drug | 48 | Seeking Alpha | ||
| 01.05. | CytomX Therapeutics Inc.: CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024 | 42 | GlobeNewswire (USA) | ||
| 22.04. | CytomX upgraded to Neutral at J.P Morgan | 18 | Seeking Alpha | ||
| 03.04. | CytomX Achieves $5M Astellas Milestone | 249 | Contract Pharma | ||
| 03.04. | CytomX Therapeutics Inc.: CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY T-Cell Engaging Bispecific (TCB) Collaboration with Astellas | 248 | GlobeNewswire (Europe) | - Achievement of latest clinical candidate triggers additional $5 million milestone payment to CytomX and is the third milestone achieved in the collaboration to date - - CytomX-retains US co-commercialization... ► Artikel lesen | |
| 22.03. | CytomX Therapeutics, Inc. - 8-K, Current Report | 7 | SEC Filings | ||
| 21.03. | CytomX Therapeutics executive sells shares worth over $6,000 | 8 | Investing.com | ||
| 12.03. | CytomX falls as Bristol Myers ends deal for cancer therapy | 25 | Seeking Alpha |
Seite:
1 2 3 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| GAMESTOP | 7.091 |
| EVOTEC | 5.673 |
| TUI | 5.233 |
| PLUG POWER | 3.716 |
| AMC ENTERTAINMENT | 3.367 |
| NEL | 3.363 |
| BAYER | 2.615 |
| SIEMENS ENERGY | 2.444 |
| RHEINMETALL | 2.268 |
| NVIDIA | 2.251 |
| COMMERZBANK | 2.043 |
| AIXTRON SE | 1.803 |
| DEUTSCHE BANK | 1.771 |
| ALLIANZ | 1.696 |
| RWE | 1.632 |
| MERCEDES-BENZ | 1.582 |
| THYSSENKRUPP | 1.562 |
| BYD | 1.500 |
| THYSSENKRUPP NUCERA | 1.480 |
| SUPER MICRO COMPUTER | 1.424 |
| RENK GROUP | 1.395 |
| VOLKSWAGEN | 1.313 |
| NORDEX | 1.195 |
| ALIBABA | 1.153 |
| DEUTSCHE TELEKOM | 1.132 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
